US FDA Requirements for Importing Generic Medicines

Quick answer: To legally import generic medicines into the United States, the specific product must have FDA approval through an Abbreviated New Drug Application (ANDA), the manufacturing facility must be FDA-registered and inspected, and every shipment must clear entry review by US Customs and Border Protection (CBP) working alongside the FDA. Importers also need to check the product and facility against the FDA’s Import Alert list, since a facility flagged under Detention Without Physical Examination (DWPE) status can have its shipments held automatically at the port of entry, regardless of how solid the paperwork otherwise looks.

If you’ve ever had a container sit at a US port for weeks while your broker chases down FDA paperwork, you already know that importing generic medicines into the United States is a different sport than importing almost anything else. It’s not a matter of tariffs and customs codes. It’s a matter of whether the FDA considers your product, your manufacturer, and your supply chain trustworthy enough to let across the border at all.

This guide breaks down exactly what the FDA requires — from the manufacturer’s side and the importer’s side — and, just as importantly, where shipments actually get stuck in practice.

Key Takeaways

• Every generic drug entering the US needs an approved ANDA tied to that specific formulation, strength, and manufacturing site.
• The manufacturing facility must be FDA-registered and subject to periodic FDA inspection, wherever in the world it’s located.
• Import Alerts and Detention Without Physical Examination (DWPE) status can block shipments automatically, even from an otherwise ANDA-approved product line.
• CBP and the FDA jointly review entries; documentation gaps are one of the most common reasons for delay, not just outright non-compliance.
• Working with a US Agent and confirming the manufacturer’s current inspection status before shipping saves far more time than fixing problems after a container is already detained.

Why FDA Requirements Are Stricter Than Most Other Import Markets

The United States runs the largest single pharmaceutical market in the world, and the FDA treats drug imports with a level of scrutiny that surprises a lot of first-time exporters and importers alike. Unlike some markets where a WHO-GMP certificate and a straightforward customs declaration get a shipment through, the US system layers product-specific approval, facility-specific registration, and shipment-specific screening on top of each other. Miss any one layer, and the product doesn’t move — no matter how solid the other two are.

This isn’t bureaucratic excess for its own sake. The FDA’s approach grew out of decades of drug safety incidents, both domestic and tied to imported products, and out of a simple structural reality: the FDA can’t physically inspect every pill crossing the border, so it relies on a system of approvals, registrations, and risk-based screening to decide what gets a closer look and what doesn’t.

For importers, understanding this system isn’t optional. It’s the difference between a predictable, repeatable supply chain and a business that lives shipment to shipment, hoping nothing gets flagged.

The Three Layers of FDA Requirements

It helps to think about FDA import requirements as three separate, stacked layers. All three need to be satisfied before a shipment clears.

Layer 1: Product Approval (ANDA)

A generic drug can only be legally sold in the US if it has an approved Abbreviated New Drug Application (ANDA). Unlike a New Drug Application (NDA), which requires full clinical trials, an ANDA relies on demonstrating bioequivalence to an already-approved reference listed drug (RLD) — proving the generic delivers the same active ingredient, in the same amount, at the same rate, into the bloodstream as the brand-name original.

The ANDA is tied to specifics: the exact formulation, strength, dosage form, and — critically — the exact manufacturing site where it’s produced. You can’t swap in a different, unapproved facility and expect the same ANDA to cover it. If a manufacturer wants to shift production of an FDA-approved generic to a new plant, that requires a supplement to the existing ANDA and, typically, a fresh facility inspection.

Layer 2: Facility Registration and Inspection

Separately from product approval, every facility manufacturing drugs for the US market — regardless of where in the world it’s located — must register with the FDA and list the drugs it produces. Registration alone doesn’t mean a facility is cleared; the FDA also conducts periodic inspections (routine surveillance inspections, pre-approval inspections tied to a specific ANDA, and for-cause inspections triggered by a specific concern) against Current Good Manufacturing Practice (CGMP) requirements under 21 CFR Parts 210 and 211.

Foreign facilities exporting to the US are also required to designate a US Agent — a US-based individual or firm who serves as the FDA’s point of contact for that facility, including receiving communications and, in some circumstances, being present during FDA interactions.

Layer 3: Import Entry Review

Even with an approved ANDA and a compliant facility, each individual shipment still passes through an entry review process at the port of entry, jointly handled by CBP and the FDA. This is where documentation, product identity verification, and risk-based screening come together. It’s also the layer where Import Alerts and DWPE status apply — meaning a shipment can be automatically detained here even when the underlying approval and facility status are technically in order, if the specific manufacturing site or product category has been flagged.

Understanding FDA Import Alerts (And Why They Matter More Than Most Importers Realize)

An FDA Import Alert is a public notice that tells CBP and FDA field staff to treat products from a specific manufacturer, or a specific product category, as high-risk enough to warrant automatic action at the border — most commonly Detention Without Physical Examination (DWPE).

Here’s the part that catches importers off guard: DWPE doesn’t require the FDA to prove there’s a problem with your specific shipment. Once a facility or product category is on an active Import Alert, shipments can be detained automatically, and the burden shifts to the importer to prove the product should be released — typically by providing private laboratory analysis or other evidence demonstrating the specific shipment meets requirements, a process that takes real time and real money.

Import Alerts get issued for reasons ranging from serious CGMP violations found during an inspection, to data integrity concerns, to repeated product quality failures. They can apply narrowly (a specific manufacturer, a specific product line) or broadly (an entire product category from a country or region, in less common cases).

The practical takeaway: never assume a manufacturer’s import status based on their last known inspection outcome. Import Alert status can change, and a facility that was clear eighteen months ago may not be clear today.

How to Check FDA Import Alert Status Before You Ship

This is a step far too many importers skip, and it takes only a few minutes:

• Search the FDA’s Import Alert database directly using the manufacturer’s name and facility address
• Cross-check the manufacturer’s FDA facility registration number (FEI number) against any listed alerts
• Ask the manufacturer directly whether any of their product lines or facilities currently carry DWPE status, and request documentation of their most recent inspection outcome
• If the manufacturer has had a recent inspection with an Official Action Indicated (OAI) classification, treat that as a serious warning sign even if a formal Import Alert hasn’t been issued yet, since OAI classifications frequently precede one

Common Reasons Generic Drug Shipments Get Detained at US Ports

Detentions rarely come down to a single dramatic failure. More often, it’s a combination of smaller gaps that add up.

Missing or incomplete ANDA reference on entry documentation. CBP and FDA entry review checks whether the product on the shipment matches an approved application. If the entry documentation doesn’t clearly tie the shipment to the correct ANDA number, formulation, and manufacturing site, expect a hold while it gets sorted out.

Facility not properly registered or registration lapsed. FDA facility registrations require annual renewal. A facility that’s fallen out of compliance on registration renewal, even for an otherwise fully approved product, can trigger entry problems.

Labeling discrepancies. US drug labeling requirements are specific — proper NDC (National Drug Code) numbers, required warnings, and packaging that matches what was approved in the ANDA. Even minor mismatches between labeling and the approved application can flag a shipment for closer review.

Import Alert or DWPE status on the manufacturer or product category. As covered above, this is one of the more common and most disruptive triggers, precisely because it applies automatically rather than requiring a fresh inspection of that specific shipment.

Incomplete or inconsistent Certificate of Analysis (CoA) documentation. Entry review often includes checking whether batch-specific quality documentation lines up with what’s expected for an approved product.

Products not properly declared under the correct classification. Errors in how a broker classifies the shipment (HTS codes, product category declarations) can trigger holds even when the underlying product is fully compliant, simply because the paperwork doesn’t match what FDA systems expect to see.

What Importers Need to Have in Place

For a US pharmacy distributor or importer bringing in generic medicines, here’s what typically needs to be lined up before the first shipment moves, not after.

Verify the ANDA Status Directly

Don’t rely solely on a manufacturer’s claim that a product is “FDA approved.” Cross-check the ANDA directly through the FDA’s Orange Book (the FDA’s published list of approved drug products with therapeutic equivalence evaluations), confirming the application number, the approved manufacturing site, and the current status of the approval.

Confirm the Manufacturing Facility’s Registration and Inspection History

Request the facility’s FEI (FDA Establishment Identifier) number and confirm current registration status. Ask for the most recent FDA inspection classification — No Action Indicated (NAI), Voluntary Action Indicated (VAI), or Official Action Indicated (OAI) — since this tells you far more about real-world compliance than a certificate alone.

Establish a US Agent Relationship (for Foreign Manufacturers)

If you’re working with an overseas manufacturer, confirm they have a properly designated US Agent on file with the FDA. This isn’t just a formality — it’s the FDA’s official channel for communication with that facility, and gaps here can complicate everything from routine correspondence to emergency response during an inspection issue.

Build a Compliant Documentation Package for Each Shipment

At minimum, this typically includes the Certificate of Analysis for the specific batch, packing list, commercial invoice, proof of ANDA linkage, and labeling that matches the approved application exactly. Working with an experienced customs broker who has specific pharmaceutical import experience — not just general cargo experience — makes a measurable difference here.

Set Up Ongoing Monitoring, Not Just Pre-Shipment Checks

Import Alert status and inspection classifications can change between shipments. Distributors moving regular volume from the same manufacturer benefit from periodically re-checking status rather than assuming the clearance from six months ago still holds.

FDA Requirements Timeline: What to Expect

A Quick Comparison: FDA vs. Other Major Regulatory Frameworks

The structural difference worth remembering: WHO-GMP, EU-GMP, and PIC/S are primarily facility certifications. FDA approval bundles facility compliance together with a product-specific application (the ANDA), which is why a facility can be fully WHO-GMP certified and still have zero FDA-approved products, simply because no ANDA has been filed and reviewed for that specific formulation.

How Entry Review Actually Works, Step by Step

Understanding what happens between “the ship docks” and “the truck leaves with your pallets” helps explain why documentation gaps cause so much friction.

Step 1: Electronic filing. Your customs broker files entry documentation electronically before or upon arrival, including product identity, manufacturer details, and the applicable FDA product code.

Step 2: Automated risk screening. FDA’s system runs an automated risk assessment based on the manufacturer, product type, and any active Import Alerts tied to that facility or product category. Most compliant shipments from facilities with a clean history clear this stage without further action.

Step 3: May May Proceed or Hold decision. If the automated screening doesn’t flag anything, CBP typically releases the shipment for delivery. If it does flag something, the shipment gets held for further review, which can mean anything from a documentation request to a physical examination.

Step 4: Documentation review or physical exam (if flagged). FDA staff may request additional documentation, or in some cases physically examine and sample the product for laboratory testing.

Step 5: Release, refusal, or DWPE-based detention. Based on the review, the shipment is either released, refused entry (requiring re-export or destruction), or, if DWPE status applies to the manufacturer or product category, automatically detained pending evidence from the importer.

Most compliant, well-documented shipments from facilities with clean inspection histories move through this in a matter of hours to a couple of days. The delays importers remember and dread almost always trace back to Steps 3 through 5.

The Role of a Pharmaceutical-Experienced Customs Broker

Not all customs brokers are equally useful here. General cargo brokers handle FDA-regulated pharmaceutical entries far less often than brokers who specialize in the category, and the difference shows up in exactly the moments that matter most — knowing which FDA product code applies, anticipating what documentation a specific product line typically triggers requests for, and knowing how to respond quickly if a shipment does get flagged. For importers moving regular volume, this is one of the higher-leverage relationships in the whole supply chain, and it’s worth treating the broker selection with the same seriousness as the manufacturer selection.

What US FDA Approval Does and Doesn’t Guarantee

It does mean:

• The specific product formulation has demonstrated bioequivalence to the reference drug through FDA-reviewed data
• The manufacturing facility has been inspected against CGMP requirements
• The product, manufacturing site, and labeling are tied together under one approved application

It doesn’t automatically mean:

• Every future shipment will clear without scrutiny — entry review happens shipment by shipment
• The facility’s compliance status is fixed forever — inspections are periodic, and status can change
• A different dosage strength or pack size of the “same” drug is automatically covered — variations often require their own approval or supplement

Red Flags When Sourcing Generic Medicines for the US Market

A supplier who can’t produce a specific ANDA number. “FDA approved” without a specific, verifiable application number tied to the exact product is not something to take at face value.

Reluctance to share recent inspection classification. A manufacturer confident in their compliance status generally won’t hesitate to discuss whether their last inspection came back NAI, VAI, or OAI.

No clearly designated US Agent for a foreign facility. This is a basic, checkable requirement, and its absence suggests either inexperience with US market requirements or something more concerning.

Pricing dramatically below comparable FDA-compliant suppliers. The compliance overhead required to maintain FDA approval status — inspection readiness, documentation systems, bioequivalence studies — is real and ongoing. A price point that seems to ignore that cost structure is worth questioning directly.

Vague answers about which specific manufacturing site produces the product you’re ordering. Some companies operate multiple facilities, only some of which carry FDA approval for a given product. Always confirm the exact site tied to your specific order.

A Realistic Example of How This Plays Out

Consider a mid-sized US pharmacy distributor sourcing a generic cardiovascular medication from an Indian manufacturer for the first time. The manufacturer’s sales team confirms the product is “FDA approved” and shares a WHO-GMP certificate as supporting documentation.

Before placing a purchase order, the distributor’s compliance team requests the specific ANDA number and cross-checks it in the FDA’s Orange Book. The application is confirmed active, tied to the correct strength and formulation, and linked to the exact manufacturing site the supplier named. The team also searches the FDA’s Import Alert database using the facility’s name and FEI number, finding no active alerts, and requests the facility’s most recent inspection classification, which comes back as Voluntary Action Indicated (VAI) with documented corrective actions already closed out.

With that verification complete, the first shipment moves through entry review without incident, clearing within about a day of arrival.

Now picture a second scenario: a different supplier, offering a similar product at a noticeably lower price, describes their product as “FDA compliant” without providing a specific ANDA number, and when asked about their facility’s FEI number, responds vaguely about “the FDA process being handled by our export partner.” A quick search of the Import Alert database using the company name the supplier operates under turns up an active DWPE listing tied to a data integrity finding from a prior inspection.

The difference between these two outcomes isn’t about which supplier had better marketing materials — it’s entirely about which claims held up under five minutes of direct verification against public FDA records.

What an FDA Facility Inspection Actually Looks Like

For manufacturers supplying the US market, FDA inspections tend to be more intensive than what a WHO-GMP or even many other national GMP inspections involve, and they’re frequently unannounced for foreign facilities as well, particularly for routine surveillance visits.

Inspectors typically spend several days on-site, reviewing not just whether SOPs exist but whether raw data — batch records, laboratory testing results, deviation investigations — tells a consistent story. A particular focus in FDA inspections is data integrity: whether electronic records show evidence of manipulation, whether audit trails are intact, and whether out-of-specification results were properly investigated rather than quietly retested until a passing result appeared. This emphasis is a large part of why FDA inspection outcomes (NAI, VAI, OAI) carry so much weight in the eyes of experienced importers — a clean classification reflects scrutiny that goes well beyond a facility walkthrough.

At the close of an inspection, if concerns are identified, the FDA issues a Form 483 listing observations. The manufacturer then has a defined window to respond with corrective actions. Depending on severity, this can resolve quietly through follow-up correspondence, or escalate to a warning letter and, in serious or unresolved cases, an Import Alert.

Sample Documentation Checklist for Each Shipment

Brokers and compliance teams vary slightly in exactly what they request, but a well-prepared shipment package for generic medicines entering the US typically includes the following:

• Commercial invoice matching the declared product, quantity, and value
• Packing list detailing batch numbers and quantities per batch
• Certificate of Analysis (CoA) specific to the batch being shipped, not a generic product-level document
• Proof of ANDA linkage — application number, approved strength, and confirmation the shipment originates from the approved manufacturing site
• Bill of lading or airway bill
• FDA Prior Notice confirmation, submitted before the shipment arrives, as required for all food and drug imports under US bioterrorism-related regulations
• Labeling samples or artwork matching the approved ANDA labeling exactly, including NDC number placement
• Facility FEI number and current registration confirmation
• Import Alert clearance check, documented internally even if not required for submission, as a due-diligence record

Missing even one or two of these rarely sinks a shipment outright, but each gap adds friction, and friction is exactly what turns a routine entry into a multi-week hold while paperwork gets sorted retroactively. Importers who build this checklist into their standard purchase order process, rather than assembling it reactively after a shipment ships, consistently report fewer entry delays.

Frequently Asked Questions

Can I import generic medicines into the US without FDA approval? No. Any prescription generic drug sold in the US requires an approved ANDA tied to that specific product and manufacturing site. Importing without this approval is not legally permitted for commercial distribution.

What is the difference between an ANDA and a WHO-GMP certificate? A WHO-GMP certificate confirms a facility meets WHO’s manufacturing standards and is used widely outside the US. An ANDA is a US-specific product approval that includes facility inspection as one component, but also requires demonstrated bioequivalence data and FDA review of the full application — it’s a more comprehensive requirement specific to the US market.

What triggers an FDA Import Alert? Import Alerts are typically issued after serious CGMP violations, data integrity concerns, or repeated product quality failures identified during FDA inspections or investigations, and they can apply to a specific manufacturer, product line, or in some cases a broader category.

How do I check if a manufacturer is on an FDA Import Alert list? The FDA publishes its Import Alert list publicly, searchable by manufacturer name, country, and product category. Cross-referencing this before finalizing a supplier relationship is a basic and worthwhile due diligence step.

What happens if my shipment gets detained under DWPE? The importer typically needs to submit evidence — often private laboratory testing or additional documentation — demonstrating the specific shipment meets FDA requirements before the FDA will consider releasing it, a process that adds real time and cost compared to a routine entry.

Does every batch need FDA testing before import? Not as a blanket requirement, but batch-specific documentation, including a Certificate of Analysis, is generally expected as part of entry review, and Import Alert status can trigger a requirement for additional independent testing on a shipment-by-shipment basis.

Can a facility lose FDA approval after already being cleared once? Yes. FDA approval status isn’t permanent and unconditional. Ongoing compliance is verified through periodic inspections, and serious findings can lead to warning letters, Import Alerts, or in more severe cases, consent decrees affecting the facility’s ability to continue supplying the US market.

Is a US Agent the same as an importer of record? No. A US Agent represents the foreign manufacturing facility in communications with the FDA. An importer of record is the entity responsible for the shipment’s compliance at the point of entry, including customs and duty obligations. Some businesses handle both roles, but they are legally distinct functions.

How often does the FDA inspect foreign manufacturing facilities? Inspection frequency is risk-based rather than fixed, taking into account factors like the facility’s compliance history, the risk profile of the products manufactured, and time since the last inspection, though it’s common for compliant facilities to be reinspected every few years.

What’s the difference between NAI, VAI, and OAI inspection classifications? No Action Indicated (NAI) means no significant issues were found. Voluntary Action Indicated (VAI) means issues were found but don’t warrant formal regulatory action, provided the facility addresses them. Official Action Indicated (OAI) means the FDA found significant issues serious enough to warrant formal regulatory action, which can include warning letters or Import Alert status.

Do I need a customs bond to import generic medicines into the US? Yes, commercial importers of regulated goods, including pharmaceuticals, typically need a customs bond as part of the entry process, arranged through a licensed customs broker as part of standard import compliance, separate from FDA-specific requirements.

What is FDA Prior Notice, and is it required for pharmaceutical shipments? Prior Notice is an advance electronic notification submitted to the FDA before a regulated shipment, including drug products, arrives in the US, giving the agency time to assess risk before the goods reach port. Failure to submit it correctly and on time is itself a common cause of entry delay, independent of the product’s underlying compliance status.

Common Misconceptions That Trip Up First-Time Importers

“WHO-GMP certification is enough to satisfy the FDA.” It isn’t. WHO-GMP and FDA CGMP are related in spirit but administered entirely separately. A facility can hold a strong WHO-GMP certificate and still have no FDA-approved products, no FDA registration, or an active Import Alert. Never treat one as a substitute for verifying the other.

“If the product cleared once, it’ll clear every time.” Entry review happens shipment by shipment, and Import Alert status can change between orders. A manufacturer in good standing today isn’t guaranteed to be in good standing at your next reorder, particularly if they’ve had a routine inspection in the interim.

“A lower price from an unregistered facility is just a smaller, cheaper operation.” Sometimes that’s true. But a facility skipping FDA registration and ANDA approval isn’t operating in a gray area — it’s operating outside the legal framework for supplying the US market entirely, and any distributor knowingly or unknowingly bringing in unapproved product carries real legal and reputational exposure.

“The customs broker handles all of this, so I don’t need to check it myself.” A good broker handles the mechanics of filing and clearing entries, but verifying ANDA status, facility registration, and Import Alert history before you commit to a supplier relationship is fundamentally a sourcing and compliance decision, not a customs brokerage function. The two roles complement each other; neither replaces the other.

“FDA approval means the product is identical to the brand-name version in every respect.” Bioequivalence, which ANDA approval requires, means the generic delivers the active ingredient into the bloodstream at a comparable rate and extent — it doesn’t require identical inactive ingredients, appearance, or packaging, which is why generics can look different from their brand-name counterparts while still being fully approved equivalents.

Quick-Reference Glossary

ANDA (Abbreviated New Drug Application): The FDA application required to market a generic drug in the US, based on demonstrated bioequivalence to an already-approved reference product.

CGMP (Current Good Manufacturing Practice): The FDA’s binding manufacturing quality regulations under 21 CFR Parts 210 and 211, applicable to any facility producing drugs for the US market.

DWPE (Detention Without Physical Examination): An FDA enforcement mechanism allowing automatic detention of shipments from a flagged manufacturer or product category, without requiring inspection of that specific shipment first.

FEI (FDA Establishment Identifier): A unique number assigned to a registered manufacturing facility, used to track registration and inspection history.

Orange Book: The FDA’s published list of approved drug products, including therapeutic equivalence ratings, used to verify a generic drug’s approval status.

US Agent: A US-based representative that a foreign drug manufacturer must designate as the FDA’s official point of contact for that facility.

Reference Listed Drug (RLD): The FDA-approved brand-name or original drug product that a generic must demonstrate bioequivalence to in order to receive ANDA approval.

Form 483: A written notice issued by FDA inspectors at the close of an inspection, listing observed conditions that may constitute violations, which the facility is expected to address with corrective actions.

Prior Notice: An advance electronic filing required before a regulated shipment, including pharmaceuticals, arrives in the US, allowing the FDA to assess risk ahead of arrival.

NDC (National Drug Code): A unique identifying number assigned to each drug product marketed in the US, used across labeling, billing, and regulatory tracking.

Related Reading for Importers Building a Compliance Checklist

If FDA import requirements are one piece of a broader sourcing strategy, it’s worth also getting familiar with:

• How WHO-GMP certification works, for suppliers also serving non-US markets
• MHRA import rules for medicines entering the UK, if you’re sourcing across multiple regulated markets
• How to verify a manufacturer’s Certificate of Pharmaceutical Product before signing a supply agreement
• What a strong pharmaceutical quality agreement should include, regardless of destination market

The Bottom Line

Importing generic medicines into the United States isn’t a single approval you check off once — it’s three layers that all have to hold at the same time: an approved ANDA for the exact product, a properly registered and inspected facility, and a clean entry review for every individual shipment. The importers who move product predictably are the ones who verify all three before committing to a supplier, monitor Import Alert status on an ongoing basis rather than a one-time check, and work with brokers and manufacturers who treat FDA compliance as a continuous discipline rather than a box checked once at the start of the relationship.

Given how much can shift between inspections — a facility’s classification, an Import Alert status, even labeling requirements — the safest approach is treating verification as a habit built into every purchase order, not a one-time step you complete when the relationship begins.

That habit doesn’t need to be complicated. A five-minute check of the Orange Book, a quick search of the Import Alert database, and a direct question to your supplier about their most recent inspection classification will catch the overwhelming majority of problems long before a shipment ever reaches a US port. The importers who build that discipline into their sourcing process consistently move product faster and with far fewer surprises than those who only start asking these questions after something has already gone wrong.